Pharmacological treatment of treatment-resistant depression: Towards evidence-based recommendations

Author:

Jerotić StefanORCID,Ivković MajaORCID

Abstract

Depression, a major global public health concern and leading cause of disability, necessitates effective management. This paper, as part of the development of comprehensive guidelines for the treatment of depressive disorder in Serbia, delves into the pharmacological treatment of treatment-resistant depression (TRD), focusing on augmentative and switching strategies, aiming to address the lack of response to standard treatments. The focus is on the efficacy and tolerability of various pharmacological agents, aimed at facilitating informed clinical decisions. In TRD, augmentation strategies involving atypical antipsychotics, NMDA antagonists, mood stabilizers, and other compounds are examined. Finally, the importance of an individualized approach in deciding between augmentation and switching strategies is emphasized. This narrative review aims to inform treatment guidelines and encourages a collaborative approach, which considers individual patient factors, to improve the quality of care for individuals with treatment-resistant depression.

Publisher

Centre for Evaluation in Education and Science (CEON/CEES)

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3